Drug Study
Drug Study
Drug Study
CLASSIFICATIO
N
FREQUENCY,
ROUTE
DURATION OF
OF ACTION
DRUG STUDY
ADMINISTRATION
CLOXACILLIN 0.48 ml q12 IV for Interferes Treatment of History of EENT: occasionally Observe the 10 rights of
1 week ANSTT ( ) with cell wall infections hypersensitivity y to laryngeal edema drug administration.
Brand Name: replication of caused by penicillin and Perform skin testing before
Avastoph susceptible pneumococci, cephalosporin s. Sever SKIN: urticarial, giving the medication
organisms, the Group A beta pneumonia, skin rashes, Assess patient for any signs
cell wall, hemolytic emphysema, exfoliative and symptoms of allergic
Drug Class:
rendered streptococci, and bacteremia, dermatitis response such as rash,
Anti-infective
osmotically penicillin G pericarditis, urticarial, and exfoliative
Antibiotic
unstable, sensitive Prophylaxis: dermatitis
GI: GI disturbances,
swell, bursts staphylococci. meningitis and Raised bed side rails
nausea, vomiting,
from osmotic Staphylococcal accordingly to prevent falls/
epigastric distress,
pressure; purulent and infection injury
diarrhea, and
resists the during septic arthritis Check for diarrhea, GI
flatulence, antibiotic
penicillinase major during the disturbances, nausea,
associated
action that cardiovascular and vomiting, and epigastric
pseudomembranou
inactivates acute the orthopedic distress
s colitis
penicillin. stage. Sub surgery. As appropriate, review all
conjunctival infections. other significant adverse
GU: interstitial
reactions and interactions,
nephritis and
especially those related to
vasculitis
the drugs.
HEMATOLOGIC:
eosinophilia,
agranulocytosis,
anemia,
thrombocytopenia,
transient rise in
transaminases and
alkaline
phosphatase
OTHER:
hypersensitivity
reactions, serum
sickness-like
reactions, fever